Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of [14C]-DZD8586 in Healthy Adult Male Participants
NCT07454863Phase 1Completed
- Sponsor
- Dizal Pharmaceutical Co., Ltd.
- Start
- Mar 2026
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of birelentinib in non-Hodgkin lymphoma (NHL), sponsored by Dizal Pharmaceutical Co., Ltd. Primary endpoints: Total amount and recovery of the radioactive dose in urine and feces and Metabolic profiling of relative abundance and metabolite identification. Started Mar 2026; status: completed.
02
Drugs
birelentinib
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT07454863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07454863.